Nice timing for glitazones

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 5, 2003, Pages 366-367

  Bailey, Clifford J ^a   Day, Caroline ^a   Krentz, Andrew J ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

EMEA; NICE; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG USE; LICENSING; MONOTHERAPY; PRACTICE GUIDELINE; UNITED KINGDOM;

EID: 0242351186     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030051001     Document Type: Article

References (9)

1. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis 2001; 1:7-13.
2. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999;16:179-92.
3. Bailey CJ, Day C, Krentz AJ. Glitazone guidelines: clarity or confusion? Prescriber 2001;66-9.
4. National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 63, 2003.
5. National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 9, 2000.
6. National Institute for Clinical Excellence (NICE). Technology appraisal guidance No. 21, 2001.
7. European Agency for the Evaluation of Medicinal Products (EMEA). www.emea.eu.int
8. Food and Drug Administration (FDA). www.fda.gov
9. Barnett D. Personal communication to AJK, 2003.